Literature DB >> 25278288

Redundancy and interaction of thrombin- and collagen-mediated platelet activation in tail bleeding and carotid thrombosis in mice.

Yamini S Bynagari-Settipalli1, Ivo Cornelissen1, Daniel Palmer1, Daniel Duong1, Cherry Concengco1, Jerry Ware1, Shaun R Coughlin2.   

Abstract

OBJECTIVE: Current antiplatelet strategies to prevent myocardial infarction and stroke are limited by bleeding risk. A better understanding of the roles of distinct platelet-activating pathways is needed. We determined whether platelet activation by 2 key primary activators, thrombin and collagen, plays distinct, redundant, or interacting roles in tail bleeding and carotid thrombosis in mice. APPROACH AND
RESULTS: Platelets from mice deficient for the thrombin receptor protease-activated receptor-4 (Par4) and the collagen receptor glycoprotein VI protein (GPVI) lack responses to thrombin and collagen, respectively. We examined tail bleeding and FeCl3-induced carotid artery occlusion in mice lacking Par4, GPVI, or both. We also examined a series of Par mutants with increasing impairment of thrombin signaling in platelets. Ablation of thrombin signaling alone by Par4 deficiency increased blood loss in the tail bleeding assay and impaired occlusive thrombus formation in the carotid occlusion assay. GPVI deficiency alone had no effect. Superimposing GPVI deficiency on Par4 deficiency markedly increased effect size in both assays. In contrast to complete ablation of thrombin signaling, 9- and 19-fold increases in EC50 for thrombin-induced platelet activation had only modest effects.
CONCLUSIONS: The observation that loss of Par4 uncovered large effects of GPVI deficiency implies that Par4 and GPVI made independent, partially redundant contributions to occlusive thrombus formation in the carotid and to hemostatic clot formation in the tail under the experimental conditions examined. At face value, these results suggest that thrombin- and collagen-induced platelet activation can play partially redundant roles, despite important differences in how these agonists are made available to platelets.
© 2014 American Heart Association, Inc.

Entities:  

Keywords:  collagen; glycoprotein VI; hemostasis; mouse assays; platelets; protease-activated receptor-3; protease-activated receptor-4; thrombin; thrombosis

Mesh:

Substances:

Year:  2014        PMID: 25278288      PMCID: PMC4239193          DOI: 10.1161/ATVBAHA.114.304244

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  42 in total

1.  Expression and function of the mouse collagen receptor glycoprotein VI is strictly dependent on its association with the FcRgamma chain.

Authors:  B Nieswandt; W Bergmeier; V Schulte; K Rackebrandt; J E Gessner; H Zirngibl
Journal:  J Biol Chem       Date:  2000-08-04       Impact factor: 5.157

Review 2.  Pathophysiologic implications of membrane phospholipid asymmetry in blood cells.

Authors:  R F Zwaal; A J Schroit
Journal:  Blood       Date:  1997-02-15       Impact factor: 22.113

3.  Effect of testosterone, sex and age on experimentally induced arterial thrombosis.

Authors:  A Uzunova; E Ramey; P W Ramwell
Journal:  Nature       Date:  1976-06-24       Impact factor: 49.962

4.  A patient with platelets deficient in glycoprotein VI that lack both collagen-induced aggregation and adhesion.

Authors:  M Moroi; S M Jung; M Okuma; K Shinmyozu
Journal:  J Clin Invest       Date:  1989-11       Impact factor: 14.808

5.  Actions of thrombin and other coagulant and proteolytic enzymes on blood platelets.

Authors:  M G Davey; E F Lüscher
Journal:  Nature       Date:  1967-12-02       Impact factor: 49.962

6.  PAR3 is a cofactor for PAR4 activation by thrombin.

Authors:  M Nakanishi-Matsui; Y W Zheng; D J Sulciner; E J Weiss; M J Ludeman; S R Coughlin
Journal:  Nature       Date:  2000-04-06       Impact factor: 49.962

7.  The contribution of glycoprotein VI to stable platelet adhesion and thrombus formation illustrated by targeted gene deletion.

Authors:  Kazunobu Kato; Taisuke Kanaji; Susan Russell; Thomas J Kunicki; Kenichi Furihata; Sachiko Kanaji; Patrizia Marchese; Armin Reininger; Zaverio M Ruggeri; Jerry Ware
Journal:  Blood       Date:  2003-05-08       Impact factor: 22.113

8.  Thrombin overcomes the thrombosis defect associated with platelet GPVI/FcRgamma deficiency.

Authors:  Pierre Mangin; Cindy L Yap; Christelle Nonne; Sharelle A Sturgeon; Isaac Goncalves; Yuping Yuan; Simone M Schoenwaelder; Christine E Wright; Francois Lanza; Shaun P Jackson
Journal:  Blood       Date:  2006-01-03       Impact factor: 22.113

9.  Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study.

Authors:  H D Lewis; J W Davis; D G Archibald; W E Steinke; T C Smitherman; J E Doherty; H W Schnaper; M M LeWinter; E Linares; J M Pouget; S C Sabharwal; E Chesler; H DeMots
Journal:  N Engl J Med       Date:  1983-08-18       Impact factor: 91.245

10.  Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.

Authors:  Deepak L Bhatt; Eric J Topol
Journal:  Am Heart J       Date:  2004-08       Impact factor: 4.749

View more
  16 in total

1.  Diacylglycerol kinase ζ is a negative regulator of GPVI-mediated platelet activation.

Authors:  Alyssa J Moroi; Nicole M Zwifelhofer; Matthew J Riese; Debra K Newman; Peter J Newman
Journal:  Blood Adv       Date:  2019-04-09

2.  The isothiocyanate sulforaphane modulates platelet function and protects against cerebral thrombotic dysfunction.

Authors:  Scarlett Gillespie; Paul M Holloway; Felix Becker; Francesca Rauzi; Shantel A Vital; Kirk A Taylor; Karen Y Stokes; Michael Emerson; Felicity N E Gavins
Journal:  Br J Pharmacol       Date:  2018-07-03       Impact factor: 8.739

3.  Role of the CD39/CD73 Purinergic Pathway in Modulating Arterial Thrombosis in Mice.

Authors:  Roman Covarrubias; Elena Chepurko; Adam Reynolds; Zachary M Huttinger; Ryan Huttinger; Katherine Stanfill; Debra G Wheeler; Tatiana Novitskaya; Simon C Robson; Karen M Dwyer; Peter J Cowan; Richard J Gumina
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-07-14       Impact factor: 8.311

Review 4.  Platelets: Context-Dependent Vascular Protectors or Mediators of Disease.

Authors:  Randal Westrick; Gabrielle Fredman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-07       Impact factor: 8.311

Review 5.  Mouse laser injury models: variations on a theme.

Authors:  Timothy J Stalker
Journal:  Platelets       Date:  2020-04-16       Impact factor: 3.862

Review 6.  Spatiotemporal regulation of coagulation and platelet activation during the hemostatic response in vivo.

Authors:  L Ivanciu; T J Stalker
Journal:  J Thromb Haemost       Date:  2015-10-23       Impact factor: 5.824

Review 7.  Functional significance of the platelet immune receptors GPVI and CLEC-2.

Authors:  Julie Rayes; Steve P Watson; Bernhard Nieswandt
Journal:  J Clin Invest       Date:  2019-01-02       Impact factor: 14.808

8.  Soluble fibrin causes an acquired platelet glycoprotein VI signaling defect: implications for coagulopathy.

Authors:  M Y Lee; C C Verni; B A Herbig; S L Diamond
Journal:  J Thromb Haemost       Date:  2017-10-27       Impact factor: 5.824

9.  Antiplatelet properties of Pim kinase inhibition are mediated through disruption of thromboxane A2 receptor signaling.

Authors:  Amanda J Unsworth; Alexander P Bye; Tanya Sage; Renato S Gaspar; Nathan Eaton; Caleb Drew; Alexander Stainer; Neline Kriek; Peter J Volberding; James L Hutchinson; Ryan Riley; Sarah Jones; Stuart J Mundell; Weiguo Cui; Hervé Falet; Jonathan M Gibbins
Journal:  Haematologica       Date:  2021-07-01       Impact factor: 9.941

10.  Fibrin activates GPVI in human and mouse platelets.

Authors:  Osama M Alshehri; Craig E Hughes; Samantha Montague; Stephanie K Watson; Jon Frampton; Markus Bender; Steve P Watson
Journal:  Blood       Date:  2015-08-17       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.